Scancell Holdings (SCLP) Price & Analysis

Compare

22 Followers

SCLP Stock Chart & Stats

9.75p

0.40p(4.06%)

At close: Jan 09 4:00 PM EST

9.75p

0.40p(4.06%)

Day’s Range― - ―

52-Week Range7.26p - 14.00p

Previous CloseN/A

Volume797.06K

Average Volume (3M)1.20M

Market Cap

£134.65M

Enterprise Value142.78M

Total Cash (Recent Filing)£8.57M

Total Debt (Recent Filing)£16.18M

Price to Earnings (P/E)―

Beta-0.02

Next Earnings

Oct 23, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)>-0.01

Shares Outstanding1,037,781,400

10 Day Avg. Volume991,653

30 Day Avg. Volume1,200,950

Financial Highlights & Ratios

PEG Ratio-0.10

Price to Book (P/B)-27.20

Price to Sales (P/S)22.14

P/FCF Ratio-17.04

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Proprietary PlatformsScancell’s ownership of differentiated platforms (T‑cell ImmunoBody and antibody engineering concepts) is a durable competitive asset. Platforms enable multiple programs, recurring licensing opportunities and partner interest, supporting long‑term pipeline breadth and non‑dilutive funding paths.

Genmab Licensing And Milestone UpsideThe Genmab license provides validation and tangible non‑operational cash (upfront revenue plus potential milestones). Such deals materially de‑risk development funding, create potential stepwise financing via milestones, and extend runway without immediate product revenues.

Clinical And Regulatory ProgressA clear PFS advantage and submitted regulatory documentation, plus confirmation of commercial‑scale manufacturing, materially reduce development and commercialization risk. Robust clinical signals and manufacturing readiness strengthen partnerability and support long‑term market access prospects.

Bears Say

Negative Shareholder EquitySustained negative equity signals capital deficits and weak solvency optics, limiting access to non‑dilutive financing and raising lender/partner caution. Combined with existing debt, this structural weakness constrains strategic flexibility and increases reliance on equity or milestone financing.

Persistent Cash BurnDespite improvement, recurring negative operating and free cash flow indicate the business structurally consumes capital to progress trials. Continued burn creates recurring financing needs, raises dilution risk, and makes the company sensitive to trial timing or milestone delays that would shorten runway.

High R&D‑driven LossesElevated R&D spend is essential for a clinical‑stage biotech but produces persistent operating losses, delaying any path to profitability. High development costs force prioritisation of programs, increase dependency on partners or financings, and amplify execution risk if key trials underperform.

Scancell Holdings News

Scancell Holdings Charts Risky but Promising Phase III Path

Scancell Holdings (($GB:SCLP)) has held its Q2 earnings call. Read on for the main highlights of the call....

20d ago

Scancell Secures FDA Green Light for Phase 3 Melanoma Trial as Pipeline and Cash Runway Advance

Scancell Holdings ( ($GB:SCLP) ) has shared an announcement. Scancell reported interim results showing strong clinical and regulatory...

21d ago

Scancell Wins FDA Nod for Phase 3 Melanoma Trial of iSCIB1+ After Strong Phase 2 Data

Scancell Holdings ( ($GB:SCLP) ) has shared an update. Scancell has secured FDA clearance for an Investigational New...

24d ago

Scancell Sets Date for Interim Results as Cancer Immunotherapy Portfolio Advances

Scancell Holdings ( ($GB:SCLP) ) has shared an update. Scancell Holdings will publish its interim financial results for...

28d ago

Scancell’s iSCIB1+ Shows Promising Results in Melanoma Trial

An update from Scancell Holdings ( ($GB:SCLP) ) is now available. Scancell Holdings has announced positive updated data...

2M ago

Scancell’s iSCIB1+ Shows Promising Results in Melanoma Treatment

The latest update is out from Scancell Holdings ( ($GB:SCLP) ). Scancell Holdings announced positive Phase 2 trial...

3M ago

Scancell Holdings Successfully Passes AGM Resolutions

Scancell Holdings ( ($GB:SCLP) ) has provided an announcement. Scancell Holdings announced that all resolutions at their Annual...

4M ago

Scancell’s Modi-1 Moditope Study: A Potential Game-Changer in Cancer Treatment

Scancell Holdings (($GB:SCLP)) announced an update on their ongoing clinical study. Scancell Holdings is conducting a Phase 1/2...

4M ago

SCLP

SCOPE Study: Scancell’s Promising Melanoma Vaccine Trials

Scancell Holdings (($GB:SCLP)) announced an update on their ongoing clinical study. The SCOPE Study, officially titled ‘A Phase...

4M ago

SCLP

Scancell Holdings Announces AGM and Annual Report Release

An update from Scancell Holdings ( ($GB:SCLP) ) is now available. Scancell Holdings plc has announced the release...

5M ago

SCLP FAQ

What was Scancell Holdings PLC’s price range in the past 12 months?

Scancell Holdings PLC lowest share price was 7.26p and its highest was 14.00p in the past 12 months.

What is Scancell Holdings PLC’s market cap?

Scancell Holdings PLC’s market cap is £134.65M.

When is Scancell Holdings PLC’s upcoming earnings report date?

Scancell Holdings PLC’s upcoming earnings report date is Oct 23, 2026 which is in 246 days.

How were Scancell Holdings PLC’s earnings last quarter?

Scancell Holdings PLC released its earnings results on Jan 29, 2026. The company reported -0.006p earnings per share for the quarter, missing the consensus estimate of N/A by -0.006p.

Is Scancell Holdings PLC overvalued?

According to Wall Street analysts Scancell Holdings PLC’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Scancell Holdings PLC pay dividends?

Scancell Holdings PLC does not currently pay dividends.

What is Scancell Holdings PLC’s EPS estimate?

Scancell Holdings PLC’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Scancell Holdings PLC have?

Scancell Holdings PLC has 1,037,781,400 shares outstanding.

What happened to Scancell Holdings PLC’s price movement after its last earnings report?

Scancell Holdings PLC reported an EPS of -0.006p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.804%.

Which hedge fund is a major shareholder of Scancell Holdings PLC?

Currently, no hedge funds are holding shares in GB:SCLP

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Scancell Holdings Stock Smart Score

Neutral

Technicals

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

-2.06%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Scancell Holdings PLC

Scancell Holdings plc, a clinical stage biopharmaceutical company, engages in the discovery and development of novel vaccines and antibody medicines to treat unmet needs in cancer and infectious diseases. The company's product candidates include SCIB1, which is in phase II clinical trial for the treatment of metastatic melanoma; SCIB2 for the treatment of non-small cell lung cancer; and Modi-1 that is in phase I/II clinical trials for the treatment of head and neck, triple negative breast, ovarian, and renal cancers. It also develops Modi-2, which targets homocitrullinated cancer antigens. In addition, the company develops SCOV1 and SCOV2 COVIDITY, a prophylactic DNA vaccine against the SARS-CoV-2 virus. Scancell Holdings plc was founded in 1997 and is based in Oxford, the United Kingdom.